Review
Oncology
Dirk Stefani, Till Ploenes, Jan Viehof, Kaid Darwiche, Martin Stuschke, Martin Schuler, Clemens Aigner
Summary: Neoadjuvant immunotherapy is a promising approach for lung cancer patients, aiming to eliminate micrometastasis, reduce recurrence rates, and improve survival by activating the immune system. Ongoing studies are evaluating the impact of this treatment on surgical outcomes and overall survival rates.
Review
Oncology
Z. Eroglu, T. O. Topcu, H. M. Yu, K. A. Margolin
Summary: Brain metastases are a common and deadly complication of advanced melanoma. Recent advancements in systemic treatment and radiation therapy have greatly improved the outcomes for patients with brain metastases. Highly active systemic therapy has shown significant benefits, despite concerns about its ability to cross the blood-brain barrier. Factors such as neurologic symptoms, number and size of brain metastases, extracranial disease status, and BRAF mutation status should be considered when determining the best treatment approach.
Article
Oncology
Lilv Fan, Guiliang Xu, Jingjing Cao, Min Li, Huihui Zhang, Fanlin Li, Xinyue Qi, Xiaoqing Zhang, Zeyu Li, Ping Han, Xuanming Yang
Summary: This study found that IFNa can directly inhibit the progression of CRPC, reduce the number of G-MDSCs in the tumor microenvironment, and weaken their inhibitory function on T cell activation, providing a potential strategy for the clinical treatment of CRPC.
Article
Multidisciplinary Sciences
Dominik Gulyas, Gabor Kovacs, Istvan Jankovics, Laszlo Meszaros, Marta Lorincz, Bela Denes
Summary: The study on immunotherapy demonstrated that the CpG + anti-OX40 group showed increased antitumor activity compared to the other two groups, prolonging the survival times of the mice.
Article
Oncology
Min Fang, Qingqing Hang, Haitao Jiang, Lei Cai, Jinlin Hu, Hangjie Ying, Qing Gu, Xiaofu Yu, Jinshi Liu, Xiaojing Lai
Summary: This study retrospectively analyzed the efficacy and safety of neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer (NSCLC) in the real world. The results showed that neoadjuvant immunotherapy plus chemotherapy has significant efficacy and tolerable adverse effects in patients with resectable stage II-III NSCLC.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Lisanne P. Zijlker, Stijn J. C. van der Burg, Christian U. Blank, Charlotte L. Zuur, W. Martin C. Klop, Michel W. M. J. Wouters, Winan J. van Houdt, Alexander C. J. van Akkooi
Summary: This study compared the surgical outcomes of patients with high-risk stage III melanoma who received neoadjuvant systemic therapy followed by lymph node dissection and those who received upfront lymph node dissection. The results showed that the surgical outcomes were comparable between the two groups.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Immunology
Jin Su, Weihong Guo, Zhian Chen, Lingzhi Wang, Hao Liu, Liying Zhao, Tian Lin, Fengping Li, Xinyuan Mao, Huilin Huang, Jiang Yu, Guoxin Li, Yanfeng Hu
Summary: This study retrospectively analyzed patients with advanced gastric cancer who underwent laparoscopic surgery after neoadjuvant immunotherapy. The results showed that combined neoadjuvant immunotherapy and chemotherapy resulted in a higher overall response rate and similar postoperative complications and recovery compared to neoadjuvant chemotherapy alone.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Cell Biology
Carlotta Cattolico, Peter Bailey, Simon T. Barry
Summary: Pancreatic ductal adenocarcinomas (PDAC) have poor responses to immunotherapy due to immunosuppressive tumor microenvironment and low infiltration of tumor CD8(+) T cells. However, alterations in tumor DNA and chemotherapy can activate immune cells, but defects in immune-sensing mechanisms in PDAC limit the effectiveness of immunotherapy.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Multidisciplinary Sciences
Elena Y. Komarova, Roman Suezov, Alina D. Nikotina, Nikolay D. Aksenov, Luiza A. Garaeva, Tatiana A. Shtam, Alexander Zhakhov, Marina G. Martynova, Olga A. Bystrova, Maria S. Istomina, Alexander M. Ischenko, Boris A. Margulis, Irina Guzhova
Summary: The release of Hsp70 chaperone from tumor cells can trigger a full-scale and effective anti-tumor immune response when specifically treated cancer cells generate Hsp70-containing EVs. This leads to enhanced NK cell toxicity towards melanoma, reduced tumor growth rate, and prolonged lifespan in animal models. Furthermore, pre-treating melanoma cells with Hsp70-enriched EVs can decrease the generation of tumor-associated macrophages, demonstrating the immunomodulatory effect of Hsp70-containing EVs.
SCIENTIFIC REPORTS
(2021)
Article
Cell Biology
Xin Chen, Xiaoshan Yang, Pingyun Yuan, Ronghua Jin, Lili Bao, Xinyu Qiu, Siying Liu, Tao Liu, John Justin Gooding, WanJun Chen, Guozhen Liu, Yongkang Bai, Shiyu Liu, Yan Jin
Summary: A novel therapeutic approach utilizing immune-homeostatic microparticles (IHMs) was developed to induce apoptosis in activated T cells, reestablish regulatory T cells, and treat multiple mouse models of autoimmunity. This strategy shows promise for efficiently treating autoimmune diseases by promoting immune tolerance.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Review
Oncology
Daniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, Mattia Alberto Di Civita, Andrea Torchia, Raffaele Giusti, Alain Jonathan Gelibter, Michela Roberto, Monica Verrico, Enrico Melis, Riccardo Taje, Fabiana Letizia Cecere, Lorenza Landi, Paola Nistico, Nicla Porciello, Mario Occhipinti, Marta Brambilla, Patrick M. Forde, Stephen V. Liu, Andrea Botticelli, Silvia Novello, Gennaro Ciliberto, Enrico Cortesi, Francesco Facciolo, Federico Cappuzzo, Daniele Santini
Summary: The use of neoadjuvant or perioperative anti-PD(L)1 therapy has shown to improve surgical outcomes, pCR rates, EFS, and OS in resectable NSCLC.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Betty C. Tong, Lin Gu, Xiaofei Wang, Dennis A. Wigle, Joseph D. Phillips, David H. Harpole Jr, Jacob A. Klapper, Thomas Sporn, Neal E. Ready, Thomas A. D'Amico
Summary: This study demonstrates that neoadjuvant pembrolizumab is safe and well tolerated in patients with non-small cell lung cancer, and it is not associated with increased surgical morbidity or mortality. Minimally invasive approaches may be more challenging in cases with neoadjuvant immunotherapy. Pathologic response is higher compared to standard neoadjuvant chemotherapy.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
(2022)
Article
Cell Biology
Filippo Birocchi, Melania Cusimano, Federico Rossari, Stefano Beretta, Paola M. Rancoita, Anna Ranghetti, Stefano Colombo, Barbara Costa, Peter Angel, Francesca Sanvito, Marcella Callea, Rossana Norata, Linda Chaabane, Tamara Canu, Antonello Spinelli, Marco Genua, Renato Ostuni, Ivan Merelli, Nadia Coltella, Luigi Naldini
Summary: In this study, the authors engineered hematopoietic stem cells ex vivo to release interferon-alpha (IFN-alpha) or interleukin-12 (IL-12) at the tumor site, and achieved effective and tolerable treatment for glioblastoma multiforme (GBM) by reprogramming the tumor immune microenvironment.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Jiawei Chen, Hongsheng Deng, Jiaxi He, Zhufeng Wang, Shuben Li
Summary: This retrospective study indicates that the time-to-surgery interval does not significantly affect the feasibility and safety of surgery in the neoadjuvant immunochemotherapy setting of non-small cell lung cancer (NSCLC). However, delayed surgery may be associated with a pathological response in NSCLC, although this association is not statistically significant.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Isabelle Serr, Maria Kral, Martin G. Scherm, Carolin Daniel
Summary: HIS mice with reprogrammed iPSCs offer a promising approach for personalized medicine and immunotherapies, enabling the study of Tregs and their role in immune activation and inhibition, thus providing insights for cancer treatment strategies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Deepak Mittal, Ailin Lepletier, Jason Madore, Amelia Roman Aguilera, Kimberley Stannard, Stephen J. Blake, Vicki L. J. Whitehall, Cheng Liu, Mark L. Bettington, Kazuyoshi Takeda, Georgina V. Long, Richard A. Scolyer, Ruth Lan, Nathan Siemers, Alan Korman, Michele W. L. Teng, Robert J. Johnston, William C. Dougall, Mark J. Smyth
CANCER IMMUNOLOGY RESEARCH
(2019)
Article
Oncology
Jing Lio, Jake S. O'Donnell, Juming Yan, Jason Madore, Stacey Allen, Mark J. Smyth, Michele W. L. Teng
Review
Oncology
Jake S. O'Donnell, Esmee P. Hoefsmit, Mark J. Smyth, Christian U. Blank, Michele W. L. Teng
CLINICAL CANCER RESEARCH
(2019)
Article
Oncology
Maya Kansara, Kristian Thomson, Puiyi Pang, Aurelie Dutour, Lisa Mirabello, Francine Acher, Jean-Philippe Pin, Elizabeth G. Demicco, Juming Yan, Michele W. L. Teng, Mark J. Smyth, David M. Thomas
Article
Oncology
Xian-Yang Li, Achim K. Moesta, Christos Xiao, Kyohei Nakamura, Mika Casey, Haiyan Zhang, Jason Madore, Ailin Lepletier, Amelia Roman Aguilera, Ashmitha Sundarrajan, Celia Jacoberger-Foissac, Clifford Wong, Tracy dela Cruz, Megan Welch, Alana G. Lerner, Bradley N. Spatola, Vanessa B. Soros, John Corbin, Ana C. Anderson, Maike Effern, Michael Hoelzel, Simon C. Robson, Rebecca L. Johnston, Nicola Waddell, Corey Smith, Tobias Bald, Nishamol Geetha, Courtney Beers, Michele W. L. Teng, Mark J. Smyth
Article
Immunology
Huimeng Wang, Lars Kjer-Nielsen, Mai Shi, Criselle D'Souza, Troi J. Pediongco, Hanwei Cao, Lyudmila Kostenko, Xin Yi Lim, Sidonia B. G. Eckle, Bronwyn S. Meehan, Tianyuan Zhu, Bingjie Wang, Zhe Zhao, Jeffrey Y. W. Mak, David P. Fairlie, Michele W. L. Teng, Jamie Rossjohn, Di Yu, Barbara Fazekas de St Groth, George Lovrecz, Louis Lu, James McCluskey, Richard A. Strugnell, Alexandra J. Corbett, Zhenjun Chen
SCIENCE IMMUNOLOGY
(2019)
Article
Oncology
Juming Yan, Stacey Allen, Elizabeth McDonald, Indrajit Das, Jeffrey Y. W. Mak, Ligong Liu, David P. Fairlie, Bronwyn S. Meehan, Zhenjun Chen, Alexandra J. Corbett, Antiopi Varelias, Mark J. Smyth, Michele W. L. Teng
Article
Oncology
Juming Yan, Xian-Yang Li, Amelia Roman Aguilera, Christos Xiao, Celia Jacoberger-Foisac, Bianca Nowlan, Simon C. Robson, Courtney Beers, Achim K. Moesta, Nishamol Geetha, Michele W. L. Teng, Mark J. Smyth
CANCER IMMUNOLOGY RESEARCH
(2020)
Article
Oncology
Ailin Lepletier, Jason Madore, Jake S. O'Donnell, Rebecca L. Johnston, Xian-Yang Li, Elizabeth McDonald, Elizabeth Ahern, Anna Kuchel, Melissa Eastgate, Sally-Ann Pearson, Domenico Mallardo, Paolo A. Ascierto, Daniela Massi, Barbara Merelli, Mario Mandala, James S. Wilmott, Alexander M. Menzies, Charles Leduc, John Stagg, Bertrand Routy, Georgina Long, Richard A. Scolyer, Tobias Bald, Nicola Waddell, William C. Dougall, Michele W. L. Teng, Mark J. Smyth
CLINICAL CANCER RESEARCH
(2020)
Article
Cell Biology
Camille Guillerey, Kimberley Stannard, Jason Chen, Sophie Krumeich, Kim Miles, Kyohei Nakamura, Jessica Smith, Yuan Yu, Susanna Ng, Heidi Harjunpaa, Michele W. L. Teng, Christian Engwerda, Gabrielle T. Belz, Mark J. Smyth
Summary: The study found that the growth of multiple myeloma was associated with changes in BM ILC2s, characterized by increased expression of maturation markers and reduced cytokine response. A subset of KLRG1(hi)ILC2s which preferentially accumulated in the liver and spleen was identified.
IMMUNOLOGY AND CELL BIOLOGY
(2021)
Article
Immunology
Susanna S. Ng, Fabian De Labastida Rivera, Juming Yan, Dillon Corvino, Indrajit Das, Ping Zhang, Rachel Kuns, Shashi Bhushan Chauhan, Jiajie Hou, Xian-Yang Li, Teija C. M. Frame, Benjamin A. McEnroe, Eilish Moore, Jinrui Na, Jessica A. Engel, Megan S. F. Soon, Bhawana Singh, Andrew J. Kueh, Marco J. Herold, Marcela Montes de Oca, Siddharth Sankar Singh, Patrick T. Bunn, Amy Roman Aguilera, Mika Casey, Matthias Braun, Nazanin Ghazanfari, Shivangi Wani, Yulin Wang, Fiona H. Amante, Chelsea L. Edwards, Ashraful Haque, William C. Dougall, Om Prakash Singh, Alan G. Baxter, Michele W. L. Teng, Alex Loukas, Norelle L. Daly, Nicole Cloonan, Mariapia A. Degli-Esposti, Jude Uzonna, William R. Heath, Tobias Bald, Siok-Keen Tey, Kyohei Nakamura, Geoffrey R. Hill, Rajiv Kumar, Shyam Sundar, Mark J. Smyth, Christian R. Engwerda
Article
Oncology
Charles Lin, Trishna Ballah, Michelle Nottage, Karen Hay, Benjamin Chua, Lizbeth Kenny, Paul Thomas, Michele Teng, Jacqui Keller, Trang Le, Jennifer Edmunds, Brett Hughes
Summary: This study aims to investigate the efficacy of combining curative intent chemoradiation with the PD-L1 inhibitor durvalumab for patients with unresectable advanced cSCC, focusing on complete response rate and treatment safety.
RADIATION ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Paolo A. Ascierto, Christian Blank, Reinhard Dummer, Marc S. Ernstoff, Soldano Ferrone, Bernard A. Fox, Thomas F. Gajewski, Claus Garbe, Patrick Hwu, Pawel Kalinski, Michelle Krogsgaard, Roger S. Lo, Jason J. Luke, Bart Neyns, Michael A. Postow, Sergio A. Quezada, Michele W. L. Teng, Giorgio Trinchieri, Alessandro Testori, Corrado Caraco, Iman Osman, Igor Puzanov, Magdalena Thurin
Summary: Advances in immune checkpoint therapy and targeted therapy have improved overall survival for patients with advanced melanoma, but challenges remain in patient classification, therapy selection, and prediction of treatment response. Understanding tumor microenvironment, immunity, and therapy response drives translational and clinical research in melanoma.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Christina Nalkurthi, Wayne A. Schroder, Michelle Melino, Katharine M. Irvine, Melanie Nyuydzefe, Wei Chen, Jing Liu, Michele W. L. Teng, Geoffrey R. Hill, Patrick Bertolino, Bruce R. Blazar, Gregory C. Miller, Andrew D. Clouston, Alexandra Zanin-Zhorov, Kelli P. A. MacDonald
Summary: By administrating a selective ROCK2 inhibitor, the prevention and reversal of hepatic fibrosis can be achieved through its effects on pro-inflammatory immune cell function. This study sheds light on the therapeutic potential of ROCK2 targeting in chronic liver disease and provides insights into the cellular and molecular pathways driving liver fibrosis.
Article
Oncology
Celia Jacoberger-Foissac, Stephen J. Blake, Jing Liu, Elizabeth McDonald, Hannah Triscott, Kyohei Nakamura, Mark J. Smyth, Michele W. L. Teng
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2020)